Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

TARS – Tarsus Pharmaceuticals Inc

TARS — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

12.58

Margin Of Safety %

Put/Call OI Ratio

1.07

EPS Next Q Diff

0.01

EPS Last/This Y

0.88

EPS This/Next Y

3.6

Price

68.69

Target Price

95.11

Analyst Recom

1.11

Performance Q

-13.78

Upside

-182.0%

Beta

0.67

Ticker: TARS




16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09TARS74.561.200.206923
2026-03-10TARS72.981.200.006926
2026-03-11TARS69.781.190.106941
2026-03-12TARS68.191.190.006941
2026-03-13TARS68.171.190.006941
2026-03-17TARS69.841.190.066971
2026-03-18TARS68.21.170.137014
2026-03-20TARS64.61.170.027014
2026-03-25TARS66.931.150.676534
2026-03-26TARS67.271.150.076538
2026-03-27TARS66.321.150.106557
2026-03-30TARS66.941.150.116561
2026-03-31TARS70.121.150.036566
2026-04-01TARS70.211.090.516751
2026-04-06TARS70.231.080.186789
2026-04-07TARS68.681.072.006814
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09TARS74.5141.3- -0.81
2026-03-10TARS72.9741.3- -0.81
2026-03-11TARS69.8241.3- -0.81
2026-03-12TARS68.1641.3- -0.81
2026-03-13TARS67.9641.3- -0.81
2026-03-17TARS69.8541.3- -0.81
2026-03-18TARS68.2341.3- -0.81
2026-03-19TARS66.7441.3- -0.81
2026-03-20TARS64.5137.5- -0.81
2026-03-23TARS64.2537.5- -0.84
2026-03-24TARS63.1837.5- -0.84
2026-03-25TARS66.9946.1- -0.73
2026-03-26TARS67.2946.1- -0.73
2026-03-27TARS66.2546.1- -0.73
2026-03-30TARS66.9857.6- -0.71
2026-03-31TARS70.0757.6- -0.71
2026-04-01TARS70.2557.6- -0.71
2026-04-02TARS70.0657.6- -0.71
2026-04-06TARS70.2157.6- -0.71
2026-04-07TARS68.6957.6- -0.71
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09TARS-3.50-1.8113.68
2026-03-10TARS-3.50-1.8113.68
2026-03-11TARS-2.53-1.8113.34
2026-03-12TARS-2.53-1.8113.34
2026-03-13TARS-2.53-1.8113.34
2026-03-18TARS-2.98-1.8213.34
2026-03-19TARS-2.98-1.8213.34
2026-03-20TARS-6.13-1.8213.34
2026-03-23TARS-6.13-1.8313.34
2026-03-24TARS-6.23-1.8313.34
2026-03-25TARS-6.23-1.8312.58
2026-03-26TARS-6.23-1.8312.58
2026-03-27TARS-6.03-1.8312.58
2026-03-30TARS-6.03-1.8212.58
2026-03-31TARS-6.03-1.8212.58
2026-04-01TARS-6.03-1.8212.58
2026-04-02TARS-6.03-1.8212.58
2026-04-06TARS-6.03-1.8412.58
2026-04-07TARS-6.03-1.8412.58
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

-6.03

Institutional Transactions

-1.84

Beta

0.67

Average Sales Estimate Current Quarter

153

Average Sales Estimate Next Quarter

169

Fair Value

Quality Score

50

Growth Score

54

Sentiment Score

88

Actual DrawDown %

19.4

Max Drawdown 5-Year %

-71.3

Target Price

95.11

P/E

Forward P/E

22.49

PEG

P/S

6.48

P/B

8.52

P/Free Cash Flow

EPS

-1.61

Average EPS Est. Cur. Y​

-0.71

EPS Next Y. (Est.)

2.89

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.72

Relative Volume

0.58

Return on Equity vs Sector %

-46.8

Return on Equity vs Industry %

-30.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

TARS Healthcare
$68.76
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
8/20
Pullback
17/25
Volume
11/15
Valuation
11/20
TP/AR
4/10
Options
0/10
RSI
49.6
Range 1M
51.1%
Sup Dist
0.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
36 /100
WEAK
Momentum
6/25
Growth
25/30
Estimates
4/20
Inst/Vol
1/15
Options
0/10
EPS Yr
62.7%
EPS NY
615.2%
52W%
64.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +44.6% upside
Quality
6/30
Valuation
10/30
Growth
18/25
Stability
6/10
LT Trend
1/5
Upside
+44.6%
Quality
50
Tarsus Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 370
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS

Latest News

Caricamento notizie per TARS
stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today
news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance
stock history TARS – Tarsus Pharmaceuticals Inc invest stock market
stock prices TARS premarket after hours
ticker TARS fair value insiders trading